Clin Surg | Volume 4, Issue 1 | Short Communication | Open Access

Treatment by Using the Endoscopic Thoracic Sympathectomy and the Autologous Bone Marrow Monocytes Transplantation for Raynaud�s Disease

Choe MH1, Schmidt SC2*, Ryu YJ1, Jo S1, Ryang MC1, Pak SR1 and Pak KJ3

1Department of Thoracic Surgery, Kim II Sung University, Korea
2Department of Thoracic Surgery, Hospital Ernst von Bergmann (Potsdam), Germany
3Department of Oncology, Medical Oncology Institute, Korea

*Correspondance to: Sven-Christian Schmidt 

Fulltext PDF

Abstract

Objective: To analyze effects of the Endoscopic Thoracic Sympathectomy (ETS), Autologous Bone Marrow Monocytes Transplantation (ABMMT) and the combination of these procedures as ultimate treatment for patients with Raynaud’s disease.
Background: ETS was demonstrated to be effective in patients with Raynaud phenomenon and ABMMT was shown efficacious in upper extremities ischemia, such as thromboangiitis obliterans (Buerger’s disease). The combination of these two procedures is not described in the literature until now. Patients and
Methods: From January 2014 to December 2016, 60 patients with Raynaud’s phenomenon were included in this prospective study. Patients are divided into three groups. Patients in group 1 received ETS. Patients in group 2 were treated with ABMMT and patients in group 3 received the combination of ETS and ABMMT. Short-and long-term results were reviewed.
Results: After a median follow-up of 8 months, patients in group3 had a significant lesser RP attacks compared to the other groups (group 1; 70.0%, group 2; 45.0%, group 3; 25.0%; p<0.05).
Conclusion: ETS combined with ABMMT may increase long-term results in patients with Raynaud’s disease.

Keywords:

Autologous bone marrow monocyte; Thoracic sympathectomy; Raynaud’s phenomenon

Citation:

Choe MH, Schmidt SC, Ryu YJ, Jo S, Ryang MC, Pak SR, et al. Treatment by Using the Endoscopic Thoracic Sympathectomy and the Autologous Bone Marrow Monocytes Transplantation for Raynaud�s Disease. Clin Surg. 2019; 4: 2399.

Subscribe to Our Newsletter